L-303-2019

Agreement ID
L-303-2019
Lead IC
NIAID
Exclusivity
Nonexclusive
External Party
TaiMed Biologics USA, Inc
Fiscal Year
2021
Territory
Worldwide
Execution Date
Effective Date
Export Date
Technologies
TAB-3169     Broadly Neutralizing Antibodies Against HIV-1 Directed to the CD4 Binding Site of HIV Envelope Protein